Bronchietasis
Conditions
Interventions
Roxithromycin group:The patients received oral roxithromycin in roxithromycin group
Control group:The patients received no drug in control group
Sponsors
First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The diagnosis of all patients with non-cystic fibrosis bronchiectasis was confirmed as bronchiectasis on high-resolution computed tomographic (HRCT) scan of the chest; 2. Aged from 18 years to 70 years; 3. Informed consent was obtained from patient before enrollment.
Exclusion criteria
Exclusion criteria: The patients with exacerbation of bronchiectasis had been excluded according to a protocol-defined exacerbation (PDE) which O'Donnell et al set down. The PDE was prospectively defined as abnormalities in four of the following nine symptoms, signs, or laboratory findings: 1. change in sputum production (consistency, color, volume, or hemoptysis); 2. increased dyspnea (chest congestion or shortness of breath); 3. increased cough; 4. fever (>/=38 degree C); 5. increased wheezing; 6. decreased exercise tolerance, malaise, fatigue, or lethargy; 7. forced expiratory volume in 1 second or forced vital capacity decreased 10% from a previously recorded value; 8. radiographic changes indicative of a new pulmonary process; or 9. changes in chest sounds. Patients with cystic fibrosis (CF), who had documented clinical, radiologic, genotypic features and abnormal sweat test results (sweat sodium and chloride >60mmol/L) [14], had been excluded. Patients who were allergic to macrolides and patients with impaired hepatic disease or diabetes mellitus had also been excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thoracic CT scores;Marker of inflammation in sputum; | — |
Countries
China
Contacts
Public ContactXiao-Ning Zhong
First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed